Baidu
map

MOL PHARM:新疫苗既可以治疗海洛因成瘾,也可以阻止药物过量

2018-02-15 佚名 Medicalxpress

斯克里普斯研究所(TSRI)的科学家在设计安全有效的疫苗方面取得了重大的里程碑,该疫苗既可以治疗海洛因成瘾,也可以阻止致命的药物过量。他们今天发表在“分子药剂学”杂志上的研究表明,在动物模型中安全的新型抗海洛因制剂如何在室温下至少保持30天。疫苗即将准备进行人体测试。

斯克里普斯研究所(TSRI)的科学家在设计安全有效的疫苗方面取得了重大的里程碑,该疫苗既可以治疗海洛因成瘾,也可以阻止致命的药物过量。他们今天发表在“分子药剂学”杂志上的研究表明,在动物模型中安全的新型抗海洛因制剂如何在室温下至少保持30天。疫苗即将准备进行人体测试。

研究的第一作者,TSRI的研究助理Candy S. Hwang博士说:“海洛因疫苗更接近临床评估。

根据国家药物滥用研究所的统计,在2000年至2016年期间有15,446名美国人因滥用海洛因而死亡,死亡率正在上升。阿片类药物处方滥用导致海洛因滥用进一步加剧 - 研究表明阿片类止痛药使用者滥用海洛因的可能性高出40倍。

海洛因疫苗的第一个配方是由Kim D. Janda博士领导的一个小组于2013年开发的,该小组由Eli R. Callaway Jr.化学教授和TSRI的Skaggs化学生物学研究所成员组成。已经证明它在小鼠和非人灵长类动物模型中都是有效且安全的。

该疫苗通过训练免疫系统抗体识别和结合海洛因分子来发挥作用,阻止药物到达大脑。研究人员认为,阻止海洛因的高浓度将有助于消除许多复吸成瘾者重新吸毒。

Hwang说:“我们的目标是准备一种可以进入临床试验的疫苗,因此,我们正在寻找'半抗原'(海洛因分子),载体蛋白和佐剂的最佳组合,以保持疫苗的稳定性运输和储存。

研究人员调查了20种不同的载体蛋白/佐剂组合是如何起作用的,包括基于温度和储存时间的储存稳定性以及制剂是液体还是粉末。

他们在啮齿动物模型中的实验表明,最好的疫苗制剂含有称为破伤风类毒素(TT)的载体蛋白和称为明矾和CpG ODN的佐剂。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787441, encodeId=8d6c1e87441f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 26 21:49:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032320, encodeId=e35a2032320ab, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed May 09 13:49:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693225, encodeId=82241693225cc, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Mon Oct 01 05:49:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523499, encodeId=59e41523499fd, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Feb 17 02:49:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288200, encodeId=42172882005c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Feb 15 15:56:36 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
    2019-01-26 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787441, encodeId=8d6c1e87441f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 26 21:49:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032320, encodeId=e35a2032320ab, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed May 09 13:49:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693225, encodeId=82241693225cc, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Mon Oct 01 05:49:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523499, encodeId=59e41523499fd, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Feb 17 02:49:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288200, encodeId=42172882005c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Feb 15 15:56:36 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787441, encodeId=8d6c1e87441f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 26 21:49:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032320, encodeId=e35a2032320ab, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed May 09 13:49:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693225, encodeId=82241693225cc, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Mon Oct 01 05:49:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523499, encodeId=59e41523499fd, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Feb 17 02:49:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288200, encodeId=42172882005c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Feb 15 15:56:36 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
    2018-10-01 gous
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787441, encodeId=8d6c1e87441f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 26 21:49:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032320, encodeId=e35a2032320ab, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed May 09 13:49:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693225, encodeId=82241693225cc, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Mon Oct 01 05:49:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523499, encodeId=59e41523499fd, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Feb 17 02:49:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288200, encodeId=42172882005c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Feb 15 15:56:36 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787441, encodeId=8d6c1e87441f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Jan 26 21:49:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032320, encodeId=e35a2032320ab, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed May 09 13:49:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693225, encodeId=82241693225cc, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Mon Oct 01 05:49:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523499, encodeId=59e41523499fd, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Feb 17 02:49:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288200, encodeId=42172882005c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Feb 15 15:56:36 CST 2018, time=2018-02-15, status=1, ipAttribution=)]
    2018-02-15 131****1460

    学习了受益匪浅

    0

相关资讯

Nat Nanotechnol:新疫苗可提高抗体浓度和效果

科学家在《自然—纳米技术》上报告称,他们研发出一种维持毒素结构的疫苗会改善疫苗效果。 在未激活毒素基础上研制出的疫苗通常用来在不会导致病人病情加重的情况下,刺激产生针对比如大肠杆菌等细菌感染的免疫反应。一般我们利用化学手段或者加热方式让毒素失去活性,但是,这可能导致其结构改变,从而让疫苗失效。 Liangfang Zhang等人设计出一种方法,可通过采用外覆盖血红细胞膜的纳米粒子捕捉毒素的方式

病毒Mobilan有望成为抵制肿瘤的新疫苗!

癌症研究最重要的领域之一是努力扩大免疫治疗对更多患者的益处。 Roswell Park癌症研究所的科学家与Cleveland BioLabs Inc.旗下子公司Panacela Labs LLC合作进行了研究,介绍了一类新的免疫治疗方法,并提出了增加可能受益于这种新方法的患者人数的策略。该研究小组的研究报告在Oncogene杂志上发表的一项研究报告中发现,涉及先天性免疫受体TLR5。

JID:脊髓灰质炎新疫苗DTaP-sIPV安全有效

虽然口服脊髓灰质炎疫苗大大降低了全球感染野生型脊髓灰质炎病毒的人数,但是它可能引起疫苗相关性瘫痪型脊髓灰质炎(VAPP, vaccine-associated paralytic poliomyelitis)和疫苗衍生脊髓灰质炎病毒(VDPVs, vaccine-derived polioviruse)所致的脊髓灰质炎的蔓延。而新的灭活脊髓灰质炎病毒,如减毒的Sabin病毒株(sIPV, inac

Nature:新疫苗打破“冷链”教条 成功耐受非洲高温

在西非进行的免疫运动已经表明,疫苗能够在没有使用冰箱的情况下被交付到偏远地区,并依然保持效力。这一发现无疑挑战了数十年来的教条,即疫苗从制造到使用的每一个环节都必须保持冷却。 法国巴黎无国界医生组织(MSF)的疫苗政策顾问Julien Potet认为,这一发现开创了“一个非常积极的先例”。他介绍说,MSF于2010年在乍得开展了一项为50万人接种麻疹疫苗的行动,当时要求在11天里使用2200

Oncogene:病毒Mobilan有望成为抵制肿瘤的新疫苗!

癌症研究最重要的领域之一是努力扩大免疫治疗对更多患者的益处。 Roswell Park癌症研究所的科学家与Cleveland BioLabs Inc.旗下子公司Panacela Labs LLC合作进行了研究,介绍了一类新的免疫治疗方法,并提出了增加可能受益于这种新方法的患者人数的策略。该研究小组的研究报告在Oncogene杂志上发表的一项研究报告中发现,涉及先天性免疫受体TLR5。

Baidu
map
Baidu
map
Baidu
map